[an error occurred while processing this directive] | [an error occurred while processing this directive]
Preliminary analysis of recurrence-free survival after radical intensity-modulated radiotherapy combined with/without chemotherapy for upper cervical and thoracic esophageal cancer
Shen Wenbin1, Gao Hongmei2, Xu Jinrui1, Li Shuguang1, Li Youmei1, Zhu Shuchai1
1Department of Radiotherapy, Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China; 2Imaging Center, Shijiazhuang First Hospital, Shijiazhuang 050011, China
AbstractObjective To investigate the recurrence-free survival (RFS) and influencing factors of intensity-modulated radiotherapy±chemotherapy (IMRT±C) for the upper thoracic esophageal cancer. Methods The medical records of 168 patients with cervical and upper thoracic esophageal cancer who met the inclusion criteria from January 2011 to December 2015 were retrospectively analyzed. The RFS was calculated by the Kaplan-Meier method. Multivariate prognostic analysis was performed by Cox models. The recurrence factors were identified by the Logistics model. Results The 1-,3-,and 5-year RFS rates were 67.8%,38.0%,and 20.4%,respectively, and the median RFS was 21.9 months. The locoregional recurrence rate was 47.6%(80/168). The recurrence sites were local esophagus (n=63), regional lymph nodes (n=7), and local esophagus+regional lymph node recurrence (n=10). Multivariate analysis showed that hoarseness, cTstaging,combined with chemotherapy,95%PTV1 exposure dose and GTV average exposure dose were the influencing factors of RFS (P=0.029,<0.001,0.031,0.038,0.020). Logistics model showed that cTstaging,cNstaging,short-term efficacy,irradiationmethod,GTV maximum transverse diameter and PTV average exposure dose were the influencing factors of recurrence (P=0.046,0.022,0.001,<0.001,0.012,0.001). Conclusions Patients with cervical and upper thoracic esophageal cancer treated with radical IMRT combined with/without chemotherapy have a higher locoregional recurrence rate,and the recurrence rate is mainly the esophagus. The independent factors that affect RFS are different from the risk factors of recurrence.
Shen Wenbin,Gao Hongmei,Xu Jinrui et al. Preliminary analysis of recurrence-free survival after radical intensity-modulated radiotherapy combined with/without chemotherapy for upper cervical and thoracic esophageal cancer[J]. Chinese Journal of Radiation Oncology, 2022, 31(2): 143-148.
Shen Wenbin,Gao Hongmei,Xu Jinrui et al. Preliminary analysis of recurrence-free survival after radical intensity-modulated radiotherapy combined with/without chemotherapy for upper cervical and thoracic esophageal cancer[J]. Chinese Journal of Radiation Oncology, 2022, 31(2): 143-148.
[1] Lee DJ, Harris A, Gillette A, et al. Carcinoma of the cervical esophagus:diagnosis, management, and results[J]. South Med J, 1984, 77(11):1365-1367. DOI:10.1097/00007611-198411000-00004. [2] Gong Y, Wang S, Zhou L, et al. Dosimetric comparison using different multileafcollimeters in intensity-modulated radiotherapy for upper thoracic esophageal cancer[J]. Radiat Oncol, 2010, 5:65. DOI:10.1186/1748-717X-5-65. [3] Tong DK, Law S, Kwong DL, et al. Current management of cervical esophageal cancer[J]. World J Surg, 2011, 35(3):600-607. DOI:10.1007/s00268-010-08767. [4] Wang HW, Chu PY, Kuo KT, et al. A reappraisal of surgical management for squamous cell carcinoma in the pharyngoesophageal junction[J]. J Surg Oncol, 2006, 93(6):468-476. DOI:10.1002/jso.20472. [5] Ajani JA, D′Amico TA, ALMHANNA K, et al. Esophageal and esophagogastric junction cancers,version 1.2015[J]. J Natl ComprCancNetw, 2015, 13(2):194-227. DOI:10.6004/jnccn.2015.0028. [6] Huang SH, Lockwood G, Brierley J, et al. Effect of concurrent high-dose cisplatin chemotherapy and conformal radiotherapy on cervical esophageal cancer survival[J]. Int J Radiat Oncol Biol Phys, 2008, 71(3):735-740. DOI:10.1016/j.ijrobp.2007.10.022 5. [7] Uno T, Isobe K, Kawakami H, et al. Concurrent chemoradiation for patients with squamous cell carcinoma of the cervical esophagus[J]. Dis Esophagus, 2007, 20(1):12-18. DOI:10.1111/j.1442-2050.2007.00632.x. [8] 中国非手术治疗食管癌临床分期专家小组. 非手术治疗食管癌的临床分期标准(草案)[J]. 中华放射肿瘤学杂志,2010, 19(3):179-180. DOI:10.3760/cma.j.issn.1004-4221.2010.03.001. China Expert Group of Clinical Staging of non-Surgical Treatment of Oesophageal Cancer. Clinical staging criteria for non-surgical treatment of oesophageal cancer (draft)[J]. Chin J Radiat Oncol, 2010, 19(3):179-180. DOI:10.3760/cma.j.issn. 1004-4221.2010.03.001. [9] Bai W, Zhou Z, Zhen C, et al. Long-term efficacy of 159 cases of cervical and upper esophageal carcinoma treated with intensity modulated radiotherapy[J]. Chin J Radiol Med Prot, 2016, 36(1):28-34. DOI:10.3760/cma.j.issn.0254-5098.2016.01.005. [10] Kumabe A, Zenda S, Motegi A, et al. Long-term clinical results of concurrent chemoradiotherapy for patients with cervical esophageal squamous cell carcinoma[J]. Anticancer Res, 2017, 37(9):5039-5044. DOI:10.21873/anticanres.11919. [11] Buckstein M, Liu J. Cervical esophageal cancers:challenges and opportunities[J]. Curr Oncol Rep, 2019, 21(5):46-52. DOI:10.1007/s11912-019-0801-7. [12] Esmati E, Maddah Safaei A, Ghalehtaki R, et al. Outcomes of definitive chemoradiotherapy for cervical and upper thoracic esophageal cancers:a single-institution experience of a rare cancer[J]. J Gastrointest Cancer, 2019, 50(3):380-385. DOI:10.1007/s12029-018-0081-8. [13] Zhao L, Zhou Y, Mu Y, et al. Patterns of failure and clinical outcomes of definitive radiotherapy for cervical esophageal cancer[J]. Oncotarget, 2017, 8(13):21852-21860. DOI:10.18632/oncotarget.15665. [14] Zhang JQ, Zhang WC, Zhang BZ, et al. Clinical results of intensity-modulated radiotherapy for 250 patients with cervical and upper thoracic esophageal carcinoma[J]. Cancer Manag Res, 2019, 11:8285-8294. DOI:10.2147/CMAR. S203575. [15] Sakanaka K, Ishida Y, FujII K, et al. Long-term outcome of definitive radiotherapy for cervical esophageal squamous cell carcinoma[J]. Radiat Oncol, 2018, 13(1):7. DOI:10.1186/s13014-018-0957-6. [16] Zhu WG, Yu CH, Han JH, et al. Feasibility and short-term efficacy of simplified intensity-modulated radiotherapy and concurrent chemotherapy for neck and upper thoracic esophageal carcinoma[J]. Ai Zheng, 2009, 28(12):1265-1269. DOI:10.5732/cjc.009.10215. [17] 白文文,周志国,甄婵军,等.159例颈及胸上段食管癌调强放疗长期疗效分析[J]. 中华放射医学与防护杂志,2016, 36(1):28-34. DOI:10.3760/cma.j.issn.0254-5098.2016.01.005. Bai WW, Zhou ZG, Zhen CJ, et al. Long-term efficacy of 159 cases of cervical and upper esophageal carcinoma treated with intensity-modulated radiotherapy[J]. Chin J Radiol Med Protect, 2016, 36(1):28-34. DOI:10.3760/cma.j.issn. 0254-5098.2016.01.005. [18] 李巧芳,祝淑钗,邓文钊,等. 颈胸上段食管癌根治性放化疗靶区范围对预后生存的影响[J]. 中华放射医学与防护杂志,2019, 39(4):268-273. DOI:10.3760/cma.j.issn.0254-5098.2019.04.005. Li QF, Zhu SC, Deng WZ, et al. Clinical outcomes in different target volume for cervical and upper-thoracic esophageal cancer in definitive chemoradiotherapy[J]. Chin J Radiol Med Protect, 2019, 39(4):268-273. DOI:10.3760/cma.j.issn. 0254-5098.2019.04.005. [19] IshidaY, SakanakaK, FujIIK, et al. Intensity-modulated radiotherapy for cervical esophageal squamous cell carcinoma without hypopharyngeal invasion:dose distribution and clinical outcome[J]. J Radiat Res, 2019, 60(4):517-526. DOI:10.1093/jrr/rrz019. [20] 张芹,吴培培,苗亚丽,等. 同步整合加量调强放疗治疗颈及胸上段食管癌的临床观察[J]. 现代肿瘤医学,2017, 25(10):1568-1571. DOI:10.3969/j.issn.1672-4992.2017.10.014. Zhang Q, Wu PP, Miao YL, et al. The clinical observation of the imultaneously integrated boost intensity-modulated radiotheragy in cervical and upper thoracic esophageal carcinoma[J]. Mod Oncol, 2017, 25(10):1568-1571. DOI:10.3969/j.issn.1672-4992.2017.10.014. [21] 沈文斌,郭娜,祝淑钗,等. 选择性增加PTV单次剂量对食管癌患者预后的影响[J]. 肿瘤防治研究,2019, 46(5):463-469. DOI:10.3971/j.issn.1000-8578.2019.18.2007. Shen WB, Guo N, Zhu SC, et al. Effect of a selective increase in a single dose of PTV on the prognosis of patients with oesophageal cancer[J]. Canc Res Prev Treat, 2019, 46(5):463-469. DOI:10.3971/j.issn.1000-8578.2019.18.2007. [22] Chen F, Li J, Ai N, et al. Influence of 3D-CRT and conformal IMRT on thyroid function of patients with cervical and upper thoracic esophageal cancer and comparison of clinical efficacy[J]. Oncol Lett, 2019, 17(3):3432-3438. DOI:10.3892/ol.2019.9989. [23] Yang H, Feng C, Cai BN, et al. Comparison of three-dimensional conformal radiation therapy, intensity-modulated radiation therapy, and volumetric-modulated arc therapy in the treatment of cervical esophageal carcinoma[J]. Dis Esophagus, 2017, 30(2):1-8. DOI:10.1111/dote.12497. [24] Besson N, Pernin V, Zefkili S, et al. Evolution of radiation techniques in the treatment of mediastinal lymphoma:from 3D conformal radiotherapy (3DCRT) to intensity-modulated RT (IMRT) using helical tomotherapy (HT):a single-centre experience and review of the literature[J]. Br J Radiol, 2016, 89(1059):20150409. DOI:10.1259/bjr.20150409. [25] Zhang P, Xi M, Zhao L, et al. Clinical efficacy and failure pattern in patients with cervical esophageal cancer treated with definitive chemoradiotherapy[J]. Radiother Oncol, 2015, 116(2):257-261. DOI:10.1016/j.radonc.2015.07.011. [26] Du XX, Yu R, Wang ZF, et al. Outcomes and prognostic factors for patients with cervical esophageal cancer undergoing definitive radiotherapy or chemoradiotherapy[J]. Bosn J Basic Med Sci, 2019, 19(2):186-194. DOI:10.17305/bjbms.2019.3873. [27] Luo HS, Huang HC, Lin LX. Effect of modern high-dose versus standard-dose radiation in definitive concurrent chemo-radiotherapy on outcome of esophageal squamous cell cancer:a meta-analysis[J]. Radiat Oncol, 2019, 14(1):178. DOI:10.1186/s13014-019-1386-x. [28] Cooper JS, Guo MD, Herskovic A, et al. Chemoradiotherapy of locally advanced esophageal cancer:long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation therapy oncology group[J]. JAMA, 1999, 281(17):1623-1627. DOI:10.1001/jama.281.17.1623. [29] Minsky BD, Pajak TF, Ginsberg RJ, et al. INT0123(radiation therapy oncology group 94-05) phase Ⅲ trial of combined-modality therapy for esophageal cancer:high-dose versus standard-dose radiation therapy[J]. J Clin Oncol, 2002, 20(5):1167-1174. DOI:10.1200/JCO.2002.20.5.1167. [30] Song T, Liang X, Fang M, et al. High-dose versus conventional-dose irradiation in cisplatin-based definitive concurrent chemoradiotherapy for esophageal cancer:a systematic review and pooled analysis[J]. Expert Rev Anticancer Ther, 2015, 15(10):1157-1169. DOI:10.1586/14737140.2015.1074041. [31] 沈文斌,高红梅,许金蕊,等. 接受选择性淋巴结照射的食管鳞癌患者预后和失败模式的分析[J]. 中华放射医学与防护杂志,2020, 40(3):196-202. DOI:10.3760/j.issn.0254-5098.2020.03.007. Shen WB, Gao HM, Xu JR, et al. Prognosis and failure patterns of esophageal squamous cell carcinoma patients undergoing selective lymph node irradiation[J]. Chin J Radiol Med Protect, 2020, 40(3):196-202. DOI:10.3760/j.issn.0254-5098.2020.03.007.
2022, Vol. 31 
